Oral Semaglutide (Rybelsus) for Type 2 Diabetes
Date: October 21, 2019 Issue #:  1583Summary:  An oral formulation of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Rybelsus– Novo Nordisk) has been approved by the FDA for once-daily treatment of type 2 diabetes in adults. Semaglutide, which has been available in a subcutaneously-injected formulation(Ozempic) since 2017, is the first GLP-1 receptor agonist to become available for oral administration; the 4 other GLP-1 receptor agonists currently available in the US are administered by subcutaneous (SC) injection. (Source: The Medical Letter)
Source: The Medical Letter - September 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Adlyxine Bydureon Byetta dulaglutide Exenatide Glucophage Liraglutide lixisenatide Metformin Ozempic Rybelsus semaglutide Trulicity type 2 diabetes Source Type: research

Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (online only)
Date: October 7, 2019 Issue #:  1582Summary:  View the Expanded Table: Some Drugs for Altitude Illness, Jet Lag, and Motion Sickness (Source: The Medical Letter)
Source: The Medical Letter - September 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acetazolamide Alertec Ambien armodafinil Bonine Cialis Dexamethasone Dimenhydrinate Dramamine Edluar Gravol Hetlioz Histanil Ibuprofen insomnia Meclizine Nifedipine Nuvigil Procardia Promethazine Ramelteon Rozerem Source Type: research

Expanded Table: Antibiotics for Travelers' Diarrhea (online only)
Date: October 7, 2019 Issue #:  1582Summary:  View the Expanded Table: Antibiotics for Travelers'Diarrhea (Source: The Medical Letter)
Source: The Medical Letter - September 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Aemcolo Azithromycin Cipro Ciprofloxacin Levaquin Levofloxacin rifamycin Rifaximin Travel Travelers ' diarrhea Xifaxan Zaxine Zithromax Source Type: research

Expanded Table: Statins (online only)
Date: September 23, 2019 Issue #:  1581Summary:  View the Expanded Table: Statins (Source: The Medical Letter)
Source: The Medical Letter - September 13, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Altoprev Atorvastatin Crestor Ezallor Sprinkle Flolipid Fluvastatin Lescol Lipitor Livalo Lovastatin Pitavastatin Pravachol pravastatin Rosuvastatin simvastatin Statins Zocor Zypitamag Source Type: research

In Brief: Ezallor Sprinkle - A New Formulation of Rosuvastatin
Date: September 23, 2019 Issue #:  1581Summary:  The lipid-lowering drug rosuvastatin is now available in a sprinkle capsule formulation (Ezallor Sprinkle– Sun Pharma). Rosuvastatin tablets (Crestor, and generics) have been available since 2003.1,2The new formulation is being marketed specifically for residents of long-term care facilities who have difficulty swallowing.Ezallor Sprinkle capsules can be swallowed whole or opened and their contents sprinkled over applesauce or mixed with water for administration via nasogastric tube.For those long-term care residents who still have a reason...
Source: The Medical Letter - September 13, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Crestor Ezallor Sprinkle Rosuvastatin Statins Source Type: research

Influenza Vaccine for 2019-2020
Date: October 21, 2019 Issue #:  1583Summary:  Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication. Available vaccines and recommendations for specific patient populations for the 2019-2020 season are listed in Tables 2 and 3. (Source: The Medical Letter)
Source: The Medical Letter - August 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Afluria Agriflu baloxavir Fluad Fluarix Flublok FluceIvax flulaval FluMist Fluzone Fluzone High-Dose Heplisav-B influenza Influenza vaccine Influvac Neuraminidase inhibitors Shingrix Source Type: research

Advice for Travelers
Date: October 7, 2019 Issue #:  1582Summary:  Patients who receive pretravel advice can reduce their risk for many travel-related conditions. Vaccines recommended for travelers are reviewed in a separate issue. (Source: The Medical Letter)
Source: The Medical Letter - August 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: acetazolamide dexamethasone Adalat Aemcolo Alertec Ambien Antihistamines Arakoda armodafinil atovaquone/proguanil Azithromycin Bismuth subsalicylate Bonamine Ceralyte Chloroquine Cialis venous thromboembolism Cipro Ciproflo Source Type: research

Duaklir Pressair: Another LAMA/LABA Inhaler for COPD
Date: September 23, 2019 Issue #:  1581Summary:  The FDA has approvedDuaklir Pressair (Circassia), a fixed-dose combination of the long-acting muscarinic antagonist (LAMA) aclidinium bromide and the longacting beta2-adrenergic agonist (LABA) formoterol fumarate, for maintenance treatment of chronic obstructive pulmonary disease (COPD). Aclidinium/formoterol is the fifth LAMA/LABA combination to be approved in the US for this indication. (Source: The Medical Letter)
Source: The Medical Letter - August 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: aclidinium Anoro Ellipta Bevespi Aerosphere COPD Duaklir Pressair Formoterol Glycopyrrolate indacaterol Inspiolto Respimat Long-acting beta2-agonists Stiolto Respimat tiotropium/olodaterol Ultibro Breezehaler umeclidinium Utibr Source Type: research

Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
Date: September 23, 2019 Issue #:  1581Summary:  Lefamulin (Xenleta– Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin(Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007. (Source: The Medical Letter)
Source: The Medical Letter - August 20, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Amoxicillin Ampicillin/sulbactam Avelox Azithromycin Cefotaxime Cefpodoxime ceftaroline Ceftriaxone Chlamydophila pneumoniae Doxycycline Fluoroquinolones Haemophilus influenzae lefamulin Levaquin Levofloxacin Linezolid meth Source Type: research

Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
Date: September 23, 2019 Issue #:  1581Summary:  The FDA has approved glucagon nasal powder (Baqsimi– Lilly) for treatment of severe hypoglycemia in patients≥4 years old with diabetes.Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits (GlucaGen Hypokit, and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA(Gvoke) and is...
Source: The Medical Letter - August 20, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Baqsimi diabetes GlucaGen Hypokit glucagon Gvoke type 1 diabetes type 2 diabetes Source Type: research

In Brief: Risk of Pulmonary Thromboembolism and Death with Tofacitinib (Xeljanz)
Date: August 26, 2019 Issue #:  1579Summary:  The FDA has required updates to the labeling of the Janus kinase (JAK) inhibitor tofacitinib(Xeljanz, Xeljanz XR) based on interim results of a postmarketing safety trial that showed an increased risk of pulmonary thromboembolism and death with a dosage of 10 mg twice daily.1 Tofacitinib is approved for treatment of rheumatoid arthritis (RA),2 psoriatic arthritis, and ulcerative colitis.In the postmarketing trial, RA patients ≥50 years old taking methotrexate who had at least one cardiovascular risk factor were randomized to receive add-on treatm...
Source: The Medical Letter - August 19, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
Date: August 26, 2019 Issue #:  1579Summary:  The FDA has approvedDovato (ViiV), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir(Tivicay) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, and generics), as a once-daily complete regimen for treatment of adults with HIV-1 infection who are antiretroviral-treatment naive and have no known substitutions associated with resistance to either drug. Dolutegravir/lamivudine is the first complete regimen to be approved by the FDA for initial treatment of HIV-1 infection that contains 2 ...
Source: The Medical Letter - August 19, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Note: Zolgensma Data Manipulation
Date: August 26, 2019 Issue #:  1579Summary:  On August 6, 2019, the FDA issued a statement on data manipulation/inaccuracy issues withZolgensma, a virus vector-based gene therapy approved for one-time IV treatment of children
Source: The Medical Letter - August 19, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Drugs for Atrial Fibrillation
Date: September 9, 2019 Issue #:  1580Summary:  Treatment of atrial fibrillation includes anticoagulation, rate control, and rhythm control. US guidelines were recently updated. (Source: The Medical Letter)
Source: The Medical Letter - August 6, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Amiodarone andexanet alfa Anticoagulants apixaban Atenolol Atrial fibrillation Beta blockers Betapace Bisoprolol Brevibloc Calan Calcium-channel blockers Cardizem Cartia Carvedilol Coreg Corgard Coumadin Dabigatran Di Source Type: research

Qmiiz ODT - An Orally Disintegrating Meloxicam Tablet
Date: September 23, 2019 Issue #:  1581Summary:  The FDA has approvedQmiiz ODT (TerSera), an orally disintegrating tablet formulation of the prescription NSAID meloxicam.Qmiiz ODT, like conventional oral meloxicam tablets (Mobic, and generics), is indicated for relief of the symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA) in adults and of juvenile RA in children who weigh≥60 kg.Vivlodex, a low-dose capsule formulation of meloxicam, is FDA-approved only for management of OA pain. (Source: The Medical Letter)
Source: The Medical Letter - August 6, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Meloxicam Mobic NSAIDs Osteoarthritis Qmiiz ODT Rheumatoid arthritis Vivlodex Source Type: research

Insect Repellents
Date: August 26, 2019 Issue #:  1579Summary:  Use of insect repellents is strongly recommended by the Centers for Disease Control and Prevention (CDC) and the Environmental Protection Agency (EPA) to prevent infections transmitted by mosquitoes and ticks. Insect repellents applied to exposed skin should be used in conjunction with other preventive measures such as wearing pants and long-sleeved shirts, and avoiding outdoor activities during peak mosquito-biting times. Mosquitoes can transmit Zika, chikungunya, dengue, West Nile, eastern equine encephalitis, and yellow fever viruses, as well as...
Source: The Medical Letter - July 24, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
Date: August 26, 2019 Issue #:  1579Summary:  The FDA has approved solriamfetol (Sunosi– Jazz), a dopamine and norepinephrine reuptake inhibitor (DNRI), to improve wakefulness in adults with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). Pitolisant(Wakix), an H3-receptor antagonist/inverse agonist recently approved by the FDA for treatment of excessive daytime sleepiness in patients with narcolepsy, will be reviewed in a future issue. (Source: The Medical Letter)
Source: The Medical Letter - July 24, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Jornay PM - Evening-Dosed Methylphenidate for ADHD
Date: August 12, 2019 Issue #:  1578Summary:  The FDA has approvedJornay PM (Ironshore), a capsule formulation of methylphenidate with a delayed-release outer layer and an extended-release inner layer, for once-nightly treatment of attention-deficit hyperactivity disorder (ADHD) in patients>6 years old.Jornay PM is the first methylphenidate product to become available in the US that is taken in the evening; other long-acting methylphenidate formulations are taken in the morning. It is being marketed specifically for patients who have disruptive ADHD symptoms in the morning. (Source: The Medical Letter)
Source: The Medical Letter - July 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Adhansia ADHD Aptensio Biphentin Concerta Contempla daytrana Dexmethylphenidate Focalin Foquest Jornay PM QuiliChew Quilivant Ritalin Source Type: research

Correction: Plenvu
Date: July 29, 2019 Issue #:  1577Summary:  In our article in issue 1564 onPlenvu for colonoscopy preparation(Med Lett Drugs Ther 2019; 61:11), the comparator drug in the DAYB trial was notPrepopik, but ratherCitrafleet, a similar sodium picosulfate-based preparation that is not available in the US. Also, we said thatPlenvu can be taken as a single- or split-dose regimen; we should have said that it can be taken as two doses in a single day or split over two days. (Source: The Medical Letter)
Source: The Medical Letter - July 22, 2019 Category: Drugs & Pharmacology Authors: admin Tags: bowel preparation Cancer screening Citrafleet Colonoscopy colorectal cancer Plenvu Prepopik sodium picosulfate Source Type: research

Addendum: Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Date: July 29, 2019 Issue #:  1577Summary:  In our article onBijuva, the oral fixed-dose combination of estradiol and progesterone(Med Lett Drugs Ther 2019; 61:99), Table 1 should have included single-ingredient oral formulations of estradiol and progesterone (see below). They will be added to the table as it appears online, along with medroxyprogesterone (Provera, and generics), another single-ingredient progestin available for use in women with an intact uterus who take systemic estrogen for menopausal symptoms. Taking generic estradiol and progesterone separately may be less convenient than ...
Source: The Medical Letter - July 22, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Bijuva Bioidentical Hormones Estrogens Hot flashes Medroxyprogesterone Menopause Progestins Prometrium Provera Source Type: research

Expanded Table: Some Drugs for Smoking Cessation (online only)
Date: July 15, 2019 Issue #:  1576Summary:  View the Expanded Table: Some Drugs for Smoking Cessation (Source: The Medical Letter)
Source: The Medical Letter - July 2, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Benzhydrocodone/Acetaminophen (Apadaz) for Pain
Date: July 15, 2019 Issue #:  1576Summary:  The FDA has approvedApadaz (KemPharm), a short-acting, fixed-dose combination of benzhydrocodone and acetaminophen, for short-term management (≤14 days) of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate. Benzhydrocodone is a prodrug of hydrocodone. Fixed-dose combinations of short-acting hydrocodone and acetaminophen or ibuprofen have been available for years and are the most abused opioid products in the US.Apadaz was developed under the presumption that inclusion of the inactive prodrug wo...
Source: The Medical Letter - July 2, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acetaminophen Apadaz benzhydrocodone Ibudone Ibuprofen Norco NSAIDs Opioids Pain Tramacet tramadol Ultracet Vicoprofen Xylon Source Type: research

Drugs for Anxiety Disorders
Date: August 12, 2019 Issue #:  1578Summary:  Anxiety disorders (generalized anxiety disorder, panic disorder, social anxiety disorder, and various phobias) are the most common form of psychiatric illness. They can be treated effectively with cognitive behavioral therapy (CBT) and/or pharmacotherapy. Obsessive-compulsive disorder and posttraumatic stress disorder are now considered separate entities in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); they can also be treated with CBT and many of the same drugs. (Source: The Medical Letter)
Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alprazolam Amitriptyline Antidepressants Antihistamines Antipsychotics Atarax Ativan Beta blockers Buspirone Cannabidiol Celexa Chlordiazepoxide Cipralex Citalopram Clonazepam Clorazepate Cymbalta Diazepam Doxepin Dri Source Type: research

Cladribine (Mavenclad) for Multiple Sclerosis
Date: July 29, 2019 Issue #:  1577Summary:  The FDA has approved cladribine (Mavenclad– EMD Serono), a purine antimetabolite, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive MS (SPMS), who cannot tolerate or have had an inadequate response to other drugs indicated for treatment of M S. It is not recommended for use in patients with clinically isolated syndrome (CIS). IV cladribine, which is FDA-approved for treatment of hairy cell leukemia, has been used off-label for treatment of MS. (Sou...
Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine Copaxone dimethyl fumarate Fingolimod Gilenya Glatiramer acetate Interferon beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy siponimod T Source Type: research

Zolgensma - One-Time Gene Therapy for Spinal Muscular Atrophy
Date: July 29, 2019 Issue #:  1577Summary:  The FDA has approved onasemnogene abeparvovec-xioi (Zolgensma– Avexis), an adeno-associated virus vector-based gene therapy, for one-time IV treatment of children
Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: nusinersen onasemnogene abeparvovec spinal muscular atrophy Spinraza zolgensma Source Type: research

Bremelanotide (Vyleesi) for Hypoactive Sexual Desire Disorder
Date: July 29, 2019 Issue #:  1577Summary:  The FDA has approved bremelanotide (Vyleesi– Amag), a melanocortin receptor agonist, for subcutaneous treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Bremelanotide is not approved for use in men or postmenopausal women. It is the second drug to be approved in the US for this indication; flibanserin(Addyi), which was approved in 2015, was the first. (Source: The Medical Letter)
Source: The Medical Letter - June 27, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Addyi bremelanotide female sexual dysfunction flibanserin Vyleesi Source Type: research

Correction: Drugs for Chronic Heart Failure
Date: July 1, 2019 Issue #:  1575Summary:  In our Drugs for Chronic Heart Failure article,1 our description of the PARADIGM-HF trial comparing the combination of the ARB valsartan and the neprilysin inhibitor sacubitril(Entresto) with the ACE inhibitor enalapril for treatment of heart failure with reduced ejection fraction (HFrEF) characterized the dosage of enalapril as " suboptimal " . Some readers have objected to that characterization.The FDA-approved dosage of enalapril for treatment of HFrEF is 2.5-20 mg twice daily. In PARADIGM-HF, the dosage was capped at 10 mg twice daily, a ...
Source: The Medical Letter - June 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: ACE inhibitors ARBs Enalapril Entresto Heart Failure sacubitril Valsartan Source Type: research

Expanded Table: Drugs for Prophylaxis of Malaria (online only)
Date: July 1, 2019 Issue #:  1575Summary:  View the Expanded Table: Drugs for Prophylaxis of Malaria (Source: The Medical Letter)
Source: The Medical Letter - June 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Arakoda atovaquone/proguanil Doxycycline Malaria Malarone Mefloquine Primaquine phosphate tafenoquine Vibramycin Source Type: research

Drugs for Smoking Cessation
Date: July 15, 2019 Issue #:  1576Summary:  Smoking tobacco remains the primary preventable cause of death in the US. Smoking cessation often requires both pharmacotherapy and behavioral support. (Source: The Medical Letter)
Source: The Medical Letter - June 11, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Bupropion Champix Chantix electronic cigarettes Habitrol NicoDerm CQ Nicorette Nicotine Nicotrol Smoking cessation Thrive Tobacco dependence Varenicline Wellbutrin Zyban Source Type: research

Expanded Table: Some Drugs for Psoriasis (online only)
Date: June 17, 2019 Issue #:  1574Summary:  View the Expanded Table: Some Drugs for Psoriasis (Source: The Medical Letter)
Source: The Medical Letter - June 10, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acitretin Adalimumab Amjevita apremilast Betamethasone Brenzys brodalumab Calcipotriene calcipotriol Calcitriol Certolizumab Cimzia Cosentyx Cyclosporine Cyltezo Dovobet Dovonex Duobril Enbrel Enstilar Erelzi Etan Source Type: research

Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
Date: July 29, 2019 Issue #:  1577Summary:  The FDA has approved cyclosporine 0.09% ophthalmic solution (Cequa– Sun) to increase tear production in patients with keratoconjunctivitis sicca (dry eye disease).Restasis, a 0.05% cyclosporine emulsion, was approved in the US in 2003 for the same indication. (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Cequa Cyclosporine Dry eye disease lifitegrast Restasis Verkazia Xiidra Source Type: research

Estradiol/Progesterone (Bijuva) for Menopausal Vasomotor Symptoms
Date: July 1, 2019 Issue #:  1575Summary:  The FDA has approvedBijuva (TherapeuticsMD), a fixed-dose combination of estradiol and progesterone, for oral treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause in women with an intact uterus. The manufacturer is marketingBijuva as " the first and only FDA-approved combination of bio-identical estradiol and bio-identical progesterone in a single daily oral capsule " . (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Activella Alora Angeliq bazedoxifene Bijuva Bioidentical Hormones Climara Combi-Patch Divigel Drospirenone Duavee Elestrin Estrogens Evamist femhrt Femring Hot flashes Medroxyprogesterone Menest Menopause Premarin Source Type: research

Colorectal Cancer Screening
Date: July 1, 2019 Issue #:  1575Summary:  Most colorectal cancers arise from localized adenomatous polyps in a process that may take 10 years or more. Early detection and removal of a precancerous colonic lesion (polyp) can prevent cancer from developing. (Source: The Medical Letter)
Source: The Medical Letter - May 29, 2019 Category: Drugs & Pharmacology Authors: admin Tags: bowel preparation Cancer screening Cologuard Colonoscopy colorectal cancer Source Type: research

Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
Date: June 3, 2019 Issue #:  1573Summary:  View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation (Source: The Medical Letter)
Source: The Medical Letter - May 24, 2019 Category: Drugs & Pharmacology Authors: admin Tags: amitiza Constella Constipation linaclotide Linzess lubiprostone Motegrity plecanatide prucalopride Resotran Trulance Source Type: research

Tafenoquine (Arakoda; Krintafel) for Malaria
Date: July 1, 2019 Issue #:  1575Summary:  The oral antimalarial tafenoquine succinate, a long-acting analog of primaquine, has been approved by the FDA in 2 different strengths.Arakoda (100-mg tablets; Sixty Degrees) is indicated for the prophylaxis of malaria in adults.Krintafel (150-mg tablets; GSK) is indicated for the prevention of relapse (radical cure) ofPlasmodium vivax malaria in patients≥16 years old undergoing treatment for acuteP. vivax infection. (Source: The Medical Letter)
Source: The Medical Letter - May 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Arakoda atovaquone/proguanil Doryx Doxycycline Insect repellents Krintafel Malaria Malarone Mefloquine Primaquine phosphate tafenoquine Source Type: research

Risankizumab (Skyrizi) for Psoriasis
Date: June 3, 2019 Issue #:  1573Summary:  The FDA has approved the interleukin (IL)-23 antagonist risankizumab-rzaa (Skyrizi– Abbvie) for treatment of moderate to severe plaque psoriasis in adults. Risankizumab is the third IL-23 antagonist to be approved for this indication; guselkumab(Tremfya) and tildrakizumab(Ilumya) were approved earlier. (Source: The Medical Letter)
Source: The Medical Letter - May 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acitretin Adalimumab apremilast brodalumab Calcipotriene calcipotriol Certolizumab Cimzia corticosteroids Cosentyx Cyclosporine Dovonex Enbrel Etanercept guselkumab Humira Ilumya Inflectra Infliximab ixekizumab Meth Source Type: research

Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Date: June 3, 2019 Issue #:  1573Summary:  The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity– Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years. (Source: The Medical Letter)
Source: The Medical Letter - May 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: amitiza Bisacodyl Constella Constipation dulcolax linaclotide Linzess lubiprostone Miralax Motegrity plecanatide Polyethylene Glycol prucalopride Resotran Restoralax Tegaserod Trulance Zelnorm Source Type: research

Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
Date: May 20, 2019 Issue #:  1572Summary:  The FDA has approved emicizumab-kxwh (Hemlibra– Genentech), a subcutaneously injected, factor IXa- and X-directed antibody, for routine prophylaxis to prevent or reduce bleeding episodes in patients with hemophilia A. Emicizumab is not recommended for treatment of bleeding. (Source: The Medical Letter)
Source: The Medical Letter - May 10, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Beriplex Eloctate emicizumab Hemlibra Hemophilia Source Type: research

Romosozumab (Evenity) for Postmenopausal Osteoporosis
Date: June 3, 2019 Issue #:  1573Summary:  The FDA has approved romosozumab-aqqg (Evenity– Amgen), a sclerostin inhibitor, for once-monthly subcutaneous (SC) treatment of osteoporosis in postmenopausal women who are at high risk for fracture (history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or cannot tolerate other drugs for this indication. R omosozumab is the first sclerostin inhibitor to be approved in the US and the third drug for treatment of postmenopausal osteoporosis that stimulates bone formation; the parathyroid hormone (PTH) receptor ag...
Source: The Medical Letter - May 1, 2019 Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Aclasta Actonel Alendronate Atelvia Binosto Bisphosphonates Boniva Denosumab Evenity Evista Forteo Fosamax Fosavance Ibandronate Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast rised Source Type: research

Inhaled Levodopa (Inbrija) for Parkinson's Disease
Date: May 20, 2019 Issue #:  1572Summary:  The FDA has approvedInbrija (Acorda), an orally inhaled dry-powder formulation of levodopa, for intermittent treatment of " off " episodes in patients with Parkinson's disease (PD) being treated with carbidopa/levodopa (Sinemet, and others). (Source: The Medical Letter)
Source: The Medical Letter - May 1, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Apokyn Apomorphine Carbidopa/levodopa Duopa Inbrija Movapo Parkinson ' s disease Rytary Sinemet Source Type: research

Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
Date: May 6, 2019 Issue #:  1571Summary:  View the Expanded Table: Some Available Insulins (Source: The Medical Letter)
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research

In Brief: Tegaserod (Zelnorm) Returns
Date: May 6, 2019 Issue #:  1571Summary:  Tegaserod maleate(Zelnorm), a 5-HT4 receptor partial agonist that increases gastrointestinal (GI) motility, was approved by the FDA in 2002 for short-term treatment of irritable bowel syndrome with constipation (IBS-C) in women and in 2004 for treatment of chronic idiopathic constipation (CIC) in adults
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Constipation irritable bowel syndrome Motegrity prucalopride Resotran Tegaserod Zelnorm Source Type: research

Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
Date: May 6, 2019 Issue #:  1571Summary:  The FDA has approved siponimod (Mayzent– Novartis), a sphingosine 1-phosphate (S1P) receptor modulator, for oral treatment of adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (initial neurological episode), relapsing-remitting disease, and active secondary progressive MS (SPMS). Siponimod i s the second S1P receptor modulator to be approved in the US; fingolimod(Gilenya), which is approved for oral treatment of relapsing forms of MS in patients≥10 years old, was the first. The purine antimetabolite ...
Source: The Medical Letter - April 26, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Cladribine dimethyl fumarate Fingolimod Gilenya Glatect Glatiramer acetate Glatopa interferod beta Lemtrada Mavenclad Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Plegridy sipo Source Type: research

Brexanolone (Zulresso) for Postpartum Depression
Date: May 6, 2019 Issue #:  1571Summary:  The FDA has approved the GABAA receptor modulator brexanolone (Zulresso– Sage Therapeutics) for IV treatment of postpartum depression (PPD). Brexanolone is the first drug to be approved by the FDA for this indication. (Source: The Medical Letter)
Source: The Medical Letter - April 16, 2019 Category: Drugs & Pharmacology Authors: admin Tags: brexanolone Depression SNRIs SSRIS Zulresso Source Type: research

Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
Date: April 22, 2019 Issue #:  1570Summary:  Eravacycline (Xerava– Tetraphase), a new synthetic tetracycline antibiotic, has been approved by the FDA for IV treatment of complicated intra-abdominal infections (cIAIs) in adults. Eravacycline is structurally similar to tigecycline (Tygacil, and generics), a broad-spectrum tetracycline approved by the FDA for IV treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired pneumonia. A higher rate of mortality has been reported with use of tigecycline compared to other antibacteri...
Source: The Medical Letter - April 15, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Ceftriaxone Doripenem eravacycline Ertapenem Escherichia coli Imipenem/cilastatin Invanz meropenem Merrem methicillin-resistant staphylococcus aureus penicillin Piperacillin/tazobactam Primaxin Pseudomonas aerugi Source Type: research

Insulins for Type 2 Diabetes
Date: May 6, 2019 Issue #:  1571Summary:  The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is
Source: The Medical Letter - April 3, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Admelog Afrezza Apidra Basaglar degludec Detemir Fiasp glargine Humalog Humulin insulin Lantus levemir Liraglutide lixisenatide Novolin Novolog Novorapid ReliOn Soliqua Toujeo Tresiba type 2 diabetes Xultophy Source Type: research

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
Date: May 20, 2019 Issue #:  1572Summary:  The FDA has approved omadacycline (Nuzyra– Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults. (Source: The Medical Letter)
Source: The Medical Letter - April 3, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Antibacterials Avelox Bactrim Cefadroxil Ceftriaxone Cephalexin Clindamycin Dicloxacillin Doxycycline Haemophilus influenzae Levofloxacin Linezolid Moxifloxacin Mycoplasma pneumoniae Nuzyra omadacycline skin and skin struct Source Type: research

Drugs for Psoriasis
Date: June 17, 2019 Issue #:  1574Summary:  Mild to moderate psoriasis can be treated with topical drugs or with phototherapy. Patients with moderate to severe disease generally require systemic therapy. (Source: The Medical Letter)
Source: The Medical Letter - April 3, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acitretin Adalimumab Amjevita apremilast Betamethasone Brenzys brodalumab Calcipotriene calcipotriol Calcitriol Certolizumab Cimzia Cosentyx Cyclosporine Cyltezo Dovobet Dovonex Duobril Elidel Enbrel Enstilar Erel Source Type: research

Expanded Table: Some Drugs for HFrEF (online only)
Date: April 8, 2019 Issue #:  1569Summary:  View the Expanded Table: Some Drugs for HFrEF (Source: The Medical Letter)
Source: The Medical Letter - March 29, 2019 Category: Drugs & Pharmacology Authors: admin Source Type: research

Ozenoxacin 1% Cream (Xepi) for Impetigo
Date: April 22, 2019 Issue #:  1570Summary:  The FDA has approved a 1% cream formulation of ozenoxacin (Xepi– Cutanea), a nonfluorinated quinolone antibiotic, for treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients≥2 months old. (Source: The Medical Letter)
Source: The Medical Letter - March 20, 2019 Category: Drugs & Pharmacology Authors: admin Tags: Acne Altabax Antibacterials Bactroban Cephalexin Dicloxacillin Impetigo methicillin-resistant staphylococcus aureus mupirocin Ozanex ozenoxacin Retapamulin Xepi Source Type: research